Global demand for organ transplant immunosuppressant drugs market was valued at approximately USD 4.51 billion in 2018, and is expected to generate revenue of around USD 5.79 billion by end of 2025, growing at a CAGR of around 3.7% between 2019 and 2025.
The report covers forecast and analysis for the organ transplant immunosuppressant drugs market on a global and regional level. The study provides historic data from 2016 along with forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the organ transplant immunosuppressant drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the organ transplant immunosuppressant drugs market on a global as well as regional level.
In order to give the users of this report a comprehensive view on the organ transplant immunosuppressant drugs market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the organ transplant immunosuppressant drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug class launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the organ transplant immunosuppressant drugs market on global and regional basis.
The study provides a crucial view on the organ transplant immunosuppressant drugs by segmenting the market based on drug class, Transplant Type, and region. All the segments of organ transplant immunosuppressant drugs market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.
Organ transplant refers to a medical procedure wherein donor organ is transplanted in body of a recipient to replace missing or damaged organ. Autograft is transplant type wherein organs or tissues are transplanted in the same person’s body. Allograft can be from cadaveric or living source and refers to transplant between two subjects of the same species. Organ transplantation is usually done no other treatment works or in case of end state organ failure such as kidney, heart, liver failure. The immune system may attack the newly transplanted organ if donor and recipients are not matched. Transplant rejection is quite common and the person with transplanted organ has to take immunosuppressant drugs for lifetime.
The demand for organ transplant immunosuppressant drugs market is driven by growing demand for transplantation, increasing investment for research and development in tissue engineering, technological advancements in organ transplant. Increasing chronic disease burden is another factor that is contributing to the organ transplant immunosuppressant drugs market growth. However, low availability of organs and high cost of overall transplantation procedure may hamper the market growth.
Based on drug class, global organ transplant immunosuppressant drugs market is bifurcated into antibodies, steroids, mTOR inhibitor, antiproliferative agents and calcineurin inhibitors. Calcineurin inhibitors drug class segment held largest market share in 2018 whereas antibodies segment is expected to exhibit highest CAGR over the forecast period. Calcineurin inhibitors drug class includes majorly two drugs cyclosporine and tacrolimus. These effective drugs have widely been used for almost 20 years.
Based on transplant type global organ transplant immunosuppressant drugs market is bifurcated into pancreas, lung, heart, liver, kidney and other. Kidney transplant was the most common transplant type across the globe in 2018. This is attributed to comparatively easy availability of donor organs compared to other organs. Also, kidney transplant is more cost effective as compared to prolonged periods of dialysis.
Based on distribution channel global organ transplant immunosuppressant drugs market is segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Hospital pharmacies held leading market share in 2018 since it is most widely preferred channel of distribution.
North America represents developed regional market for organ transplant immunosuppressant drugs. Presence of favorable reimbursement policies, presence of developed healthcare facilities, technological advancements, increasing healthcare spending are major factors driving the market growth in this region. Europe was second largest market in 2018. Asia Pacific is projected to witness rapid CAGR for organ transplant immunosuppressant drugs market. Dense population base, increasing chronic disease burden, increasing healthcare expenditure, introduction of favorable reimbursement policies are expected to boost market growth in Asia Pacific. Latin America is will register noticeable growth over the forecast period. Middle East and Africa will register sluggish growth in the years to come as a result of lack of advanced healthcare infrastructure.
Major players included in the report are Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Mylan Laboratories, Inc., Novartis AG, Accord Healthcare Ltd., Sanofi Genzyme, and Astellas Pharma, Inc. among others.
The report segment of global organ transplant immunosuppressant drugs market as follows:
Global Organ Transplant Immunosuppressant Drugs Market: By Drug Class
Global Organ Transplant Immunosuppressant Drugs Market: By Transplant Type
Global Organ Transplant Immunosuppressant Drugs Market: By Distribution Channel
Global Organ Transplant Immunosuppressant Drugs Market: By Region